Towards multi-drug adaptive therapy

Jeffrey West[1*], Li You[2], Joel Brown[1,4,†], Paul K. Newton[3,†], Alexander R. A. Anderson[1,†,+]

1 Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
2 Department of Data Science and Knowledge Engineering, Maastricht University, Maastricht, The Netherlands
3 Department of Aerospace & Mechanical Engineering, Mathematics, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
4 Cancer Biology and Evolution Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
† These authors share senior authorship

* jeffrey.west@moffitt.org
+ alexander.anderson@moffitt.org

Abstract

Background

A new ecologically inspired paradigm in cancer treatment known as "adaptive therapy" capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment sensitive cells to survive which in turn suppress proliferation of the less fit resistant populations. This adaptive approach means that each patient's treatment is truly personalized based on the tumor's response rather than a one-size-fits-all fixed treatment regime. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments.

Methods & Findings

We present a simple extension of a previously developed model of metastatic prostate cancer to a frequency-dependent domain as a case study and point of departure to illustrate three novel concepts to aid the design of multi-drug adaptive therapies. First, frequency-dependent "cycles" of tumor evolution can trap tumor evolution in a periodic, controllable loop. Second, the availability and selection of treatments may limit the evolutionary "search space" reachable by the tumor. Third, the velocity of evolution is important to the timing of drug sequences.

Conclusions

By noting that the stated goal of adaptive therapy is to maintain a stable tumor volume while controlling the tumor composition, we can make the simplifying assumption of a (relatively) constant tumor volume. We explain the importance of modeling frequency-dependent dynamics at play within a tumor, and show how these three

concepts (evolutionary cycles, evolutionary search space, and evolutionary velocity) aid the selection of drugs and design of treatment schedules in multi-drug adaptive therapy.

Introduction

Dobzhansky's now-famous quote that "nothing in biology makes sense except in the light of evolution" succinctly explains a worldview that has been widely adopted by the cancer biology community [1]. Taken one step further, others have claimed that "nothing in evolution makes sense except in the light of ecology" which provided the basis for designing adaptive cancer therapies centered on principles from evolution and ecology [2–4].

Cancer is an evolutionary and ecological process [5,6] driven by random mutations [7,8] responsible for the genetic diversity and heterogeneity that typically arises via waves of clonal and subclonal expansions [9,10]. Clones and subclones compete on an adaptive fitness landscape in which Darwinian selection favors highly proliferative cell phenotypes, which in turn drive rapid tumor growth [5,6].

Recent emphasis on personalized medicine has largely focused on the development of therapies that target specific mutations. These targeted therapies extend patient lives but tumors tend to evolve resistance within months [11,12]. Tumor relapse and the development of resistance after therapy is the result of an evolutionary mechanism called competitive release – a process whereby pre-existing resistant cells in the tumor are selected for growth in the absence of drug-targeted, therapy-sensitive cells [13]. Targeted therapies strongly target sensitive cells in a tumor, selecting for resistant cell types and, if total eradication of all cancer cells is not accomplished, the tumor will relapse derived from resistant cells that survived initial therapy [14,15]. Continuous administration of each subsequent targeted therapy will inevitably result in the emergence of a new resistant clone (Fig. 1A). This approach ignores considerations of heterogeneity and therapy as a selection event in somatic evolution [9,16,17].

Enlightenment via evolution

Instead, eradicating most disseminated cancers may be impossible, undermining the typical goal of cancer treatment of killing as many tumor cells as possible [18,19]. Previous schools of thought dictated that maximum cell-kill will either lead to a cure or, at worst, maximum life extension. However, a recent (2012) systematic literature analysis of cancer relapse and therapeutic research showed that while evolutionary terms rarely appeared in papers studying therapeutic relapse before 1980 ($< 1\%$), the language usage has steadily increased more recently, due to a huge potential benefit of studying therapeutic relapse from an evolutionary perspective [20].

A new paradigm in the war on cancer replaces the "treatment-for-cure" strategy with "treatment-for-stability" – receiving cues from agriculturists who have similarly abandoned the goal of complete eradication of pests in favor of limited application of insecticides for control [18,21]. This ecologically inspired paradigm known as "adaptive therapy" capitalizes on subclonal competitive interactions. Resistance may confer some fitness disadvantage due to increased rate of DNA repair or active pumping out of the toxic drug across cell membranes which diverts finite energy supply that would otherwise be available for invasion into non-cancerous tissues or proliferation [13,19,22]. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment sensitive cells to survive (see Fig. 1B, blue) which in turn suppress proliferation of the less fit resistant populations (see Fig. 1B, red). Adaptive therapies have now been tested experimentally [23,23,24] and are currently being applied across multiple clinical trials (NCT02415621; NCT03511196;

Fig 1. Schematic of cancer clonal evolution under therapy. A) Conventional sequential therapy of two treatments selects for a clone resistant to treatment one (red) upon tumor relapse and subsequently a clone resistant to treatment two (green). B) Adaptive therapy maintains a stable tumor volume by introducing treatment holidays. Drug sensitive clones (blue) suppress the growth of less fit resistant clones (red). However, resistance still eventually occurs. C) One proposed adaptive multi-drug strategy is to alternate between adaptive regimens of either drug. D) An alternative multi-drug adaptive strategy is the administration of both in combination with adaptive treatment holidays, leading to a doubly-resistant resistant clone (yellow).

Fig 2. A single evolutionary cycle Two drugs (purple, orange) are administered either in combination (e.g. week 1), monotherapy (week 2, 5) or no treatment (week 4). A tumor biopsy indicates the tumor composition at the end of each week, showing the evolution of four phenotypes (pie charts: blue, green, red, yellow phenotypes) over time. The goal of adaptive therapy is to maintain a stable tumor volume while controlling the tumor composition frequencies (stored in the state vector, $\vec{x}$). A frequency-dependent "cycle" is a paradigm of tumor control which employs a succession of treatments that returns the state of the tumor composition back to the initial state. A cycle of five weeks is shown here: $\vec{x}_5 \approx \vec{x}_1$.

NCT03543969; NCT03630120) at the Moffitt Cancer Center [25]. These adaptive therapies capitalize on competition for space and resources between drug-sensitive and slow growing drug-resistant populations [26–28].

Steering patient-specific evolution

This adaptive approach means that each patient's treatment is truly personalized based on the tumor's response rather than a one-size-fits-all fixed treatment regime [29]. There remain several open challenges in designing adaptive therapies. First, treatments can theoretically be used as means to steer and control somatic evolution where the tumor finds itself in an evolutionary dead end [30], an evolutionary double-bind [31,32], or evolutionarily stable control [18,27,33], yet how to design steering strategies is difficult and unclear. Second, it's not yet clear how to extend these evolutionarily enlightened therapeutic concepts to multiple treatments. Two schematic examples are illustrated in Fig. 1C and 1D. Is it evolutionarily optimal to reproduce the single drug adaptive therapy in a sequential (Fig. 1C) setting or in combination (Fig. 1D)? Synergizing treatments such that evolving resistance to one drug makes cells more

susceptible to another requires mathematical modeling as well as improved monitoring methods [34,35].

Figure 2 provides a schematic of steering the tumor into "cycles" of tumor evolution. A cycle is defined as a treatment regimen that steers the tumor into periodic and repeatable temporal dynamics of tumor composition. As seen in figure 2, a weekly biopsy shows the frequencies (pie charts) of 4 phenotypes (blue, green, red, yellow) in the evolving tumor over time. At each time step, the state of the tumor is given by a vector, $\vec{x}$, indicating the frequency of each cell type composing the tumor. In this example, the fifth week produces a tumor composition, $\vec{x}$, which is approximately equivalent to the tumor composition at the start of therapy ($\vec{x}_5 \approx \vec{x}_1$). Theoretically, such cycles could be repeated ad infinitum to steer and trap tumor evolution in a repeatable (and controllable) cycle.

A trial may use sequences of n available drugs either alone or in combination (shown for $n = 2$ in figure 2). We employ the terminology "treatment" to indicate the 2^n possible combinations: no drug, single drug, or combination therapy. These treatments can be administered in any arbitrary succession in order to control m cell types. An adaptive trial for metastatic castrate resistant prostate cancer (NCT02415621) uses only two treatments: 1. Lupron and 2. Lupron & Abiraterone. Likewise, an adaptive trial for advanced BRAF mutant melanoma (NCT03543969) administers Vemurafenib and cobimetinib in combination, followed by no treatment. Both trials use only two treatments out of the four (2^2) combinations possible with two drugs (no treatment; first drug only; second drug only; first and second drug in combination therapy). Opening up trial design to include the full range of complexity (i.e. 2^n) may allow for greater tumor control, but the treatment administered at each clinical decision time point must be chosen with care and forethought, to steer the tumor into a desirable evolutionary state.

Adaptive therapy has been attempted clinically using proxy measurements for tumor volume such as prostate-specific antigen marker (PSA) for prostate or lactate dehydrogenase (LDH) for melanoma. While these blood biomarkers are crude measurements of tumor burden, there have been many recent advances in reliable methods of monitoring tumor evolution using circulating tumor DNA as an informative, inherently specific, and highly sensitive biomarker of metastatic cancers (see [36]). As monitoring methods mature, so must methods of prediction and quantification of evolution [25,37,38]. To that end, the purpose of this paper is to introduce the following three concepts to consider in the pursuit of designing multi-drug adaptive therapies:

1. Frequency-dependent "cycles" of tumor evolution

2. Treatment-dependent evolutionary "search space"

3. Frequency-dependent evolutionary velocity

As seen in Fig. 1B,C, and D, the goal of an adaptive therapy is to maintain a stable tumor volume consisting of a substantive drug-sensitive population (blue) that is able to out-compete and suppress resistant populations (red, green, yellow). Adaptive therapy maintains a stable tumor volume in favor of controlling the tumor composition (i.e. mitigating the onset competitive release of resistance). Using this simplifying assumption of a (relatively) constant tumor volume allows us to view only the frequency dynamics of the tumor, ignoring (for the moment) population dynamics and turning to a game theoretic modelling framework. The next section explains the importance of modeling frequency-dependent dynamics (models of dynamical changes of $\vec{x}$ as shown in figure 2) and introduces a case study to illustrate these concepts.

Fig 3. Temporal dynamics under therapy. (A) A "trilinear" coordinate system represents every possible state of the tumor's 3 cell types ($\vec{x} = [x_1, x_2, x_3]$) inside the triangle. The corners represent 100% of each particular cell type while interior points represent a fraction of each cell type. (B) Temporal dynamics are traced along trajectories for Lupron treatment (blue lines with arrows). Each point inside the triangle leads to an equilibrium state of T^P and T^+ cells (blue circle). (C) Similarly, Lupron & Abiraterone treatment leads all dynamics to the 100% T^- equilibrium state (red circle). (D) The tumor still evolves without treatment, to an equilibrium of mostly T^+ cells (purple circle).

Materials and methods

Evolutionary game theory (EGT) is a mathematical framework that models
frequency-dependent selection among competing individuals on a fitness landscape.
Competition of individuals on a fitness landscape is typically characterized by a "payoff
matrix" which defines the fitness of an individual upon interactions with another
individual or the population at large [39–41]. In particular, frequency-dependent
mathematical models have shown success in modeling competitive release in cancer
treatment [13], designing optimal cancer treatment [42–44], evolutionary double
binds [31], glioblastoma progression [45], tumor-stroma interactions [46], the emergence
of invasiveness in cancer [47] as well as in co-culures of alectinib-sensitive and
alectinib-resistant non-small cell lung cancer [48].

Frequency-dependent models of tumor evolution are particularly suited for studying
tumor control (i.e. "cycles" of tumor evolution), determining the set of possible
evolutionary dynamics (i.e. evolutionary search space), and timing of evolution (i.e.
evolutionary velocity). The next section introduces a simplified extension of a
previously published model of prostate cancer [25, 49]. This case study introduces and
develops these generalizable concepts for designing multi-drug adaptive therapy
treatment schedules for three cell types (m = 3 phenotypes; figure 2) under two drug
treatments (n = 2 drugs; figure 2). In principle, the concepts applied to this particular
case study in the next section can be extended to an arbitrary number of available
treatment combinations for desired control of an arbitrary number of cell types.

Case study: metastatic castrate resistant prostate cancer

In progressive prostate cancer, intermittent androgen deprivation (IAD) is a common
treatment that generally leads to regression, albeit eventual castration-resistance [50].
Upon castrate-resistance, adaptive abiraterone has shown some treatment success.
Previously, this disease was described by a population dynamics model with three cell
types: those that require testosterone for growth, T^+, cells that require testosterone but
produce their own, T^P, or cells that are independent of testosterone, T^- [25]. This
model served to motivate a clinical trial (NCT02415621) which administers continuous
Lupron (limiting systemic testosterone production) and cycles of adaptive Abiraterone
(anti-androgen). In principle, there exist many frequency-dependent models of cell-cell
competition which could adequately characterize this system: replicator dynamics
models, stochastic Moran process models, spatially-explicit game theoretic
representations, even normalized population dynamics models. Here, we simply require
a *frequency-dependent* model: analyzing trajectories of relative population sizes rather
than absolute population sizes of m cell types under treatment from combinations of n
drugs. For details on the specific implementation and parameterization of the model
used in figures 3, 5, and 6, we refer the reader to Supplemental Information and to
refs. [25, 49].

In order to track the state vector of the tumor, $\vec{x}$, we set the variables x_1, x_2, x_3 to
the corresponding frequency of dependent (T^+), producers (T^P) and independent (T^-)
cells, respectively, such that $\sum_i x_i = 1$. The temporal dynamics of these different
populations under treatment can be characterized inside a trilinear coordinates simplex
(Fig. 3A) which gives a representation of every possible value of $\vec{x}$, on a triangle. The
corners represent a tumor consisting of 100% of either T^+ (top corner), T^P (left corner),
and T^- (right corner). Figure 3 shows the temporal dynamics under each treatment.

Every treatment scenario has an associated long-time equilibrium state: the tumor
composition where all temporal dynamics eventually converge. For example, continuous
treatment of Lupron leads to roughly equal fraction of T^+ and T^P (blue circle Fig. 3B).
Continuous treatment of Lupron & Abiraterone leads to full saturation of T^- (blue

Fig 4. Sequential treatments which lead to an evolutionary cycle. An evolutionary cycle employs a succession of sequential treatments which returns the state of the tumor composition back to the initial state at the start of treatment. (A) For example, a patient with an initial condition of roughly equal fractions of each cell type (blue circle) might be administered Lupron for some time (blue line), switch to no treatment (purple line), and switch to Lupron & Abiraterone (red line), which arrives back at the same initial condition: an evolutionary cycle. This progression can be repeated, controlling the tumor. Alternatively, the dashed line show dynamics under continuous treatment, leading to respective equilibrium states, spiralling out of the evolutionary cycle. (B) The identical evolutionary cycle paradigm is shown with cell fraction, $\vec{x}$ over time.

circle Fig. 3C). Similarly, administering no treatment leads to an equilibrium of mostly T^+ and roughly equal (but small) proportions of T^- and T^P (purple circle Fig. 3D).

Results

The goal of adaptive therapy in prostate cancer is to delay the onset of the resistant T^- population by well-timed *switching* between each treatment. This is equivalent to switching between each triangular phase portrait in figure 3 before reaching the resistant equilibrium state of any given treatment. In theory, a periodic (closed) cycle can be constructed by switching between treatments at carefully chosen times in order to design schedules that are superior to continuous maximum tolerated dose [51,52].

Searching for cycles

For example, figure 4A shows a patient with an initial condition of roughly equal fractions of each cell type (blue circle). Lupron might be administered for some time (blue line) before switching to no treatment (purple line), followed by a switch to both Lupron & Abiraterone (red line). This sequence of treatments arrives back at the same initial condition: an evolutionary cycle. This treatment sequence can be repeated, controlling the tumor. The dashed lines on figure 4A show dynamics under continuous treatment which lead to respective equilibrium states, spiralling out of the evolutionary cycle.

The identical evolutionary cycle paradigm is shown with cell fraction, $\vec{x}$ over time in figure 4B. By appropriate treatment switching, the three cell types remain in

competition with each other, and no cell type is able to dominate but instead are   179
balanced indefinitely in closed periodic cycles thereby avoiding the emergence of   180
resistance. The tumor undergoes 3 such evolutionary cycles, where the tumor "resets"   181
back the initial state before treatment (pie charts, figure 4).   182

From this perspective, adaptive therapy benefits from treatment holidays precisely   183
because these holidays help the tumor composition be pushed into an approximate cycle.   184
Yet, when slightly off, resistance still *eventually* occurs in adaptive therapy regimes 185
when not on an exact cycle (Fig. 1B, red). By observation, many such cycles exist in   186
the state space shown in Fig. 3D: for example, traveling down any Lupron trajectory   187
(blue), switching to a no treatment trajectory (purple) and so on, repeated ad infinitum. 188
Where do such cycles exist? Which cycles are preferable? To answer these questions, the   189
next section introduces concepts of evolutionary search space and evolutionary velocity. 190

Evolutionary search space   191

These same phase portraits can be drawn for each pairwise treatment combination (Fig.   192
5). Each treatment has an associated equilibrium (solid circles), which can be connected 193
by a single evolutionary trajectory. These two connecting trajectories represent a   194
bounding region of state space where a periodic cycle resulting from sequential   195
combination of the two treatments is guaranteed on the outer rim of this region   196
(directionality shown with black arrows). As can be seen in Fig. 5, all external   197
trajectories tend toward either treatment's equilibrium, or towards the inside of the   198
bounding domain. The implications are clear: sequential treatment between any two   199
drugs for a sufficiently long time results in limiting the "evolutionary search space" of 200
the tumor composition.   201

At least one cycle exists for each pairwise treatment scenario: the outer rim of the   202
absorbing state. There may be other cycles, existing only in the interior of the region. 203
For some pairwise combinations, the bounding region is quite large (see Fig. 5A: 204
Lupron ↔ Lupron & Abiraterone); for others quite small (see Fig. 5B: no treatment ↔   205
Lupron or C: no treatment ↔ Lupron & Abiraterone). Once treatment drives the tumor   206
composition into one of these bounding regions, it's impossible to traverse outside   207
without the addition of a third treatment.   208

Considering the three treatment scenarios together (see Fig. 5D: no treatment ↔   209
Lupron ↔ Lupron & Abiraterone) expands the evolutionary search space. Arbitary   210
cycles can be constructed by clever sequences of treatment inside this expanded   211
evolutionary search space. To illustrate which regions in which cycles may be preferable, 212
the next section will describe evolutionary velocity.   213

Evolutionary velocity   214

The evolutionary "velocity" (and each of its velocity components) of each treatment   215
scenario can be viewed on the same trilinear simplex, seen in Fig. 6 for no treatment (6, 216
left column), Lupron (6, middle column), and Lupron & Abiraterone (5, right column).   217
A low velocity indicates a slow change to the tumor composition (calculated as the   218
magnitude of the resultant vector of all components in eqn. 1: see Supporting   219
Information). Several recent studies have indicated the importance of studying temporal 220
effects of drug administration. Using human breast cancer explants, in vitro cells,   221
mouse in vivo studies combined with mathematical modeling, one study showed that a   222
temporary exposure to a taxane induces phenotypic cell state transition towards a   223
favored transient chemotherapy-tolerant state which disappears when the drugs are   224
administered in combination [53]. A separate study noted the appearance of weakly   225
proliferative, resistant cells under high dose therapy is transient and controllable by 226

Fig 5. Evolutionary search space under therapy. Bounded, absorbing regions
are shown for treatment pairs: Lupron ↔ Lupron & Abiraterone (A); No treatment ↔
Lupron (B); No treatment ↔ Lupron & Abiraterone, (C) and all treatments (D). The
outer rim of the absorbing region represents the largest cycle for the pair of treatments
(arrows show trajectory directionality). Any regimen will eventually be absorbed into
the bounded region (3 sample sequential regimens shown). By cleverly defining
treatment schedules (D), the bounded region can be expanded to find cycles in a wider
region of the state space. Example shown for Lupron (blue line) ⟶ no treatment
(purple line) ⟶ Lupron & Abiraterone (red line).

non-genetic, stem-like (reversible) characteristics that depend on timing and length of drug administration [54].

In short: timing matters. Introduction of combination therapy or altering the timing of sequential therapy changes the evolutionary velocity of the underlying tumor composition. One can imagine scenarios where a fast or slow evolutionary velocity is desired. A tumor with a high composition of resistant cells may need to navigate to a fast dynamics region to rapidly decrease the resistant subpopulation. Alternatively, an adaptive regime may capitalize on slow velocities regions that ensure slow evolutionary dynamics on treatment holidays.

Frequency dynamics models allow for monitoring and control of the velocity of a single cell type (see Fig. 6 D - L). For example, under continuous Lupron & Abiraterone treatment, the velocity of the T^- population is positive for most of the state space (see Fig. 6L). In order to control the T^- population, it's necessary to switch to a new treatment: Fig. 6J or Fig. 6K. Depending on the current tumor composition, no treatment or Lupron may be desirable for negative T^- velocity (blue).

Discussion

In the design of multi-drug adaptive therapy, the optimal method of combining therapies in an additive or sequential manner is unclear. A key observation is that the goal of adaptive therapy is to maintain a stable tumor volume in favor of designing therapies that alter tumor composition. We advocate for the use of frequency-dependent competition models (and in particular evolutionary game theory) to design novel multi-drug adaptive therapy regimens. This is a promising modeling approach, and more work must be done combining population models of changing tumor volume with frequency dependent models of changing tumor fraction in order to eliminate clinically unfeasible treatment schedules from consideration.

While it's clear that tumors evolve in response to treatment, it's proved difficult to exploit evolutionary principles to steer tumor evolution in an ideal direction. One limitation of current adaptive therapy clinical trials is the limited selection of drugs and limited monitoring methods. Even despite the lack of monitoring the exact state of the tumor composition, the technique of maintaining a substantial drug-sensitive population for extended tumor control has shown promise in mathematical models as well as preclinical and clinical trials. However, each of the on-going or planned adaptive therapy clinical trial utilizes less than the full range of treatment options available. For example, prostate cancer adaptive therapy sequentially administers Lupron and combination Lupron & Abiraterone, while ignoring no treatment or Abiraterone monotherapy. Similarly, the planned melanoma trial administers no treatment alternating with combination Vemurafenib and cobimetinib. The conceptual paradigms introduced here (cycles of tumor evolution, evolutionary search space, and evolutionary velocity) provide a path forward to reducing the complexity of selecting between 2^n treatment choices at every clinical decision point.

Especially when developed in collaboration with clinicians, evolutionary models of cellular competition can provide clarity and power despite their simplicity. As a first step, we have illustrated these three adaptive paradigms in a specific case study (prostate cancer) for $n = 2$ drugs controlling $m = 3$ phenotypes (testosterone producers, testosterone dependent, testosterone independent cells). These techniques can be extended to any multi-drug adaptive therapy setting. The first step is to carefully choose competition parameters (i.e. the payoff matrix) of each cell phenotype under consideration and draw the dynamical phase portraits of possible evolutionary trajectories implies by the set of competition parameters. The power of evolutionary game theory is that the *relative* fitness of each phenotype is often easy to determine,

Fig 6. Evolutionary velocity before and during therapy. Columns show evolutionary velocity of simulations identical to Fig. 3 for no treatment, lupron, and lupron+abiraterone. A-C: note that no treatment is characterized by mostly slow velocities (blue) while adding treatments increases velocities, except when approaching evolutionary stable points (circles). D - L: rows show subpopulation relative velocity for T+ (D,E,F), TP (G,H,I), and T- (J,K,L). Adaptive therapy relies on the suppression of the resistant population (T-) by the sensitive populations (T+,TP) during treatment holidays (first column). This is only possible in certain a subset of the statespace (blue; where T- velocity < 0). Velocities calculated by eqn. 1: see Supporting Information.

allowing for straightforward construction and analysis of the model. 277

Each treatment will eventually fail due to resistance. The resistant state is the 278
absorbing stable state of tumor phenotypic composition associated with continuous 279
treatment. Example trajectories for a given treatment can be plotted, predicting the 280
timing to reach this absorbing resistant state. When adding a second treatment in 281
sequence, an absorbing bounded region of phenotype space (Fig. 5) can be drawn, 282
which we term the evolutionary "search space" reachable with two or more treatments. 283
This absorbing state space is bounded by a evolutionary cycle that connects the stable 284
state points from each treatment. The search space may be be a small region (i.e. Fig. 285
5B) or large (i.e. Fig. 5A). Upon combining all treatments, the state space is expanded, 286
also leading to more options for cycles in new regions of the state space. Intuition would 287
indicate that new drugs should be introduced that have "orthogonal" stable states – 288
stable equilibria far from the equilibria of existing drugs. These orthogonal drugs open 289
up the treatment space, allowing for more options in choosing cycles (Fig. 5D). The 290
closeness of two stable states from two distinct treatments will give an idea of the 291
"orthogonality" of two treatments, aiding treatment selection, the sequential ordering of 292
treatments, and the timing of switching between treatments. 293

It is also important to note that not treating still allows the tumor to evolve. This 294
no treatment case is often associated with slow evolution due to low selection. During 295
treatment holidays used to avoid resistance to a first treatment, it may be wise to 296
choose a faster (high selection) second treatment that gives a similar resultant tumor 297
composition over the slow evolution of no treatment. Adaptive therapy is a promising 298
step towards ecologically-inspired personalized medicine. Optimizing multi-drug 299
adaptive therapy is not a straightforward task, but mathematical models are a powerful 300
abstraction of clinical intuition, enabling the generation of new treatment schedules and 301
comparisons to standard of care. 302

Acknowledgments

The authors gratefully acknowledge funding from the Physical Sciences Oncology Network (PSON) at the National Cancer Institute, U54CA193489 (supporting J. West, J. Brown and A. Anderson).

References

1. Dobzhansky T. Nothing in biology makes sense except in the light of evolution. The american biology teacher. 2013;75(2):87–91.

2. Pörtner HO, Giomi F. Nothing in experimental biology makes sense except in the light of ecology and evolution – correspondence on J. Exp. Biol. 216, 2771-2782. Journal of Experimental Biology. 2013;216(23):4494–4495. doi:10.1242/jeb.095232.

3. Brown JS. Why Darwin would have loved evolutionary game theory. Proc R Soc B. 2016;283(1838):20160847.

4. Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Translational oncology. 2008;1(4):158–164.

5. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nature Reviews Cancer. 2006;6(12):924.

6. Attolini CSO, Michor F. Evolutionary theory of cancer. Annals of the New York Academy of Sciences. 2009;1168(1):23–51.

7. Kinzler KW, Vogelstein B. The genetic basis of human cancer 2. a ed; 2002.

8. I P M Tomlinson WFB M R Novelli. The mutation rate and cancer. PNAS. 1996;93:14800–14803.

9. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306.

10. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28.

11. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. elife. 2013;2:e00747.

12. Bozic I, Nowak MA. Resisting resistance. 2017;.

13. West J, Ma Y, Newton PK. Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. Journal of Theoretical Biology. 2018;455:249 – 260. doi:https://doi.org/10.1016/j.jtbi.2018.07.028.

14. Perry MC. The Chemotherapy Source Book. Lippincott Williams & Wilkins; 2008.

15. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer. 2012;12(7):487.

16. Alfonso JCL, Jagiella N, Núñez L, Herrero MA, Drasdo D. Estimating dose painting effects in radiotherapy: a mathematical model. PloS one. 2014;9(2):e89380.

17. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British journal of cancer. 2010;103(8):1139.

18. Gatenby RA. A change of strategy in the war on cancer. Nature. 2009;459(7246):508.

19. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer research. 2009;69(11):4894–4903.

20. Aktipis CA, Kwan VS, Johnson KA, Neuberg SL, Maley CC. Overlooking Evolution: a Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research. PloS One. 2011;6(11):e26100.

21. Beckman R, Schemmarm G, Yeang C. Impact of genetic dynamics and single-cell heterogeneity on the development of personalized non-standard medicine strategies for cancer. Proc Natl Acad Sci. 2012;109(36):14586–14591.

22. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling. Science translational medicine. 2011;3(90):90ra59–90ra59.

23. Enriquez-Navas PM, Wojtkowiak JW, Gatenby RA. Application of evolutionary principles to cancer therapy. Cancer research. 2015;.

24. Kam Y, Das T, Minton S, Gatenby RA. Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistance. Women's Health. 2014;10(4):423–430.

25. Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nature communications. 2017;8(1):1816.

26. Bacevic K, Noble R, Soffar A, Ammar OW, Boszonyik B, Prieto S, et al. Spatial competition constrains resistance to targeted cancer therapy. Nature communications. 2017;8(1):1995.

27. Gallaher J, Enriquez-Navas PM, Luddy KA, Gatenby RA, Anderson AR. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer research. 2018; p. canres–2649.

28. Hansen E, Woods RJ, Read AF. How to use a chemotherapeutic agent when resistance to it threatens the patient. PLoS biology. 2017;15(2):e2001110.

29. Basanta D, Anderson A. Homeostasis Back and Forth: An Eco-Evolutionary Perspective of Cancer. bioRxiv. 2016; p. 092023.

30. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiology and Prevention Biomarkers. 2004;13(8):1375–1384.

31. Basanta D, Gatenby RA, Anderson AR. Exploiting evolution to treat drug resistance: combination therapy and the double bind. Molecular pharmaceutics. 2012;9(4):914–921.

32. Basanta D, Anderson AR. Exploiting ecological principles to better understand cancer progression and treatment. Interface focus. 2013;3(4):20130020.

33. Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS computational biology. 2009;5(11):e1000557.

34. Fischer A, Vázquez-García I, Mustonen V. The value of monitoring to control evolving populations. Proceedings of the National Academy of Sciences. 2015;112(4):1007–1012.

35. Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, et al. Classifying the evolutionary and ecological features of neoplasms. Nature Reviews Cancer. 2017;17(10):605–619.

36. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine. 2013;368(13):1199–1209.

37. Liao D, Estévez-Salmerón L, Tlsty TD. Conceptualizing a tool to optimize therapy based on dynamic heterogeneity. Physical biology. 2012;9(6):065005.

38. Lässig M, Mustonen V, Walczak AM. Predicting evolution. Nature ecology & evolution. 2017;1(3):0077.

39. Axelrod R, Axelrod DE, Pienta KJ. Evolution of cooperation among tumor cells. Proceedings of the National Academy of Sciences. 2006;103(36):13474–13479.

40. Nowak MA. Evolutionary Dynamics. Harvard University Press; 2006.

41. Hummert S, Bohl K, Basanta D, Deutsch A, Werner S, Theißen G, et al. Evolutionary game theory: cells as players. Molecular BioSystems. 2014;10(12):3044–3065.

42. K S, JS B, WS D, RA G. Optimizing cancer treatment using game theory: A review. JAMA Oncology. 2018;doi:10.1001/jamaoncol.2018.3395.

43. Orlando PA, Gatenby RA, Brown JS. Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy. Physical biology. 2012;9(6):065007.

44. West J, Robertson-Tessi M, Luddy K, Park DS, Williamson DF, Harmon C, et al. The immune checkpoint kick start: Optimization of neoadjuvant combination therapy using game theory. bioRxiv. 2018; p. 349142.

45. Basanta D, Simon M, Hatzikirou H, Deutsch A. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion. Cell proliferation. 2008;41(6):980–987.

46. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, Ayala GE, et al. The Role of Transforming Growth Factor-β–Mediated Tumor-Stroma Interactions in Prostate Cancer Progression: An Integrative Approach. Cancer research. 2009;69(17):7111–7120.

47. Basanta D, Hatzikirou H, Deutsch A. Studying the emergence of invasiveness in tumours using game theory. The European Physical Journal B. 2008;63(3):393–397.

48. Kaznatcheev A, Peacock J, Basanta D, Marusyk A, Scott JG. Fibroblasts and alectinib switch the evolutionary games that non-small cell lung cancer plays. bioRxiv. 2017; p. 179259.

49. You L, Brown JS, Thuijsman F, Cunningham JJ, Gatenby RA, Zhang J, et al. Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model. Journal of theoretical biology. 2017;435:78–97.

50. Morken JD, Packer A, Everett RA, Nagy JD, Kuang Y. Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. Cancer research. 2014;.

51. Newton PK, Ma Y. On the design of treatment schedules that avoid chemotherapeutic resistance. bioRxiv. 2018; p. 325381.

52. Newton P, Ma Y. Nonlinear dynamics of chemotherapeutic resistance. bioRxiv. 2018; p. 300582.

53. Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M, et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nature communications. 2015;6:6139.

54. Chisholm RH, Lorenzi T, Lorz A, Larsen AK, Almeida L, Escargueil A, et al. Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, non-genetic instability and stress-induced adaptation. Cancer research. 2015; p. canres–2103.

55. Cunningham JJ, Brown JS, Gatenby RA, Staňková K. Optimal Control to Develop Therapeutic Strategies for Metastatic Castrate Resistant Prostate Cancer. Journal of Theoretical Biology. 2018;.

Supporting Information

The model presented below is a simplified frequency-dependent dynamics mathematical model (a qualitative extension of the model behind the first adaptive therapy clinical trial in metastatic prostate cancer [25]). The replicator dynamics model is a frequency-dependent deterministic birth-death process in which birth and death rates are functions of cell fitness, and cell fitness is a function of prevalence in the population (eqns. 1 and 2).

$$\dot{x}_i = (f_i - \langle f \rangle)x_i \qquad (1)$$
$$f_i = w_i(A\vec{x})_i \qquad (2)$$

The variables x_1, x_2, x_3 are the corresponding frequency of dependent (T^+), producers (T^P) and independent (T^-) cells, respectively, such that $\sum_i x_i = 1$. The prevalence of each cell type changes over time according to the changing population fitness, f_i, compared to the average fitness of all three populations $\langle f \rangle = \sum_i f_i x_i$. Competitive interactions between these three cell types are summarized in the payoff matrix, A, below.

$$
\begin{array}{c}
\\
T^+ \\
T^P \\
T^-
\end{array}
\begin{array}{ccc}
T^+ & T^P & T^- \\
\begin{pmatrix}
0 & a & b \\
c & 0 & d \\
e & f & 0
\end{pmatrix}
\end{array}
\qquad (3)
$$

The fitness is calculated as the product of the payoff entries and prevalence of each population (eqn. 2). Treatments are assumed to alter the carrying capacity for each cell type. Under Lupron, each producer cell is assumed to support 1.5 dependent cells, limiting the T^+ to rely on producers in the absence of systemic testosterone. During Lupron & Abiraterone combination treatment, each producer is capable of supporting 0.5 T^+ cells and the carrying capacity of T^P cells significantly drops due to local anti-androgen effects.

In order to simulate therapy, a weighting term, w_i, is introduced, which weights the fitness by the carrying capacity of each cell type, K_i normalized by the maximum carrying capacity ($w_i = K_i/K_{\max}$ where $K_{\max} = 1.5 \cdot 10^4$ cells). Under Lupron treatment only, the carrying capacities are given by: $K_1 = 1.5 \cdot K_2$; $K_2 = 10^4$; $K_3 = 10^4$. Combination Lupron & Abiraterone carrying capacities are given by: $K_1 = 0.5 \cdot K_2$; $K_2 = 10^2$; $K_3 = 10^4$ [25]. Carrying capacities for dynamics under no treatment are given by: $K_1 = 1.5 \cdot 10^4$, $K_2 = 10^4$, $K_3 = 10^4$.

Competition parameters between cell types have also been noted and described previously, reprinted below in Table 1 (under treatment) and Table 2 (no treatment) for convenience [25, 49, 55]. Since there is cell-cell competition and niche partitioning with respect to association with surrounding vasculature, we assume that all coefficients are positive and bounded between 0 and 1. Consistent with ref. [25], two general rules are used to etermine the relative values of inter-cell type interactions: 1) T^+ cells with no exogenous testosterone are the least competitive cell type and 2) the competitive effect of T^- cells is stronger on TP cells than on T+ cells.

Unless otherwise noted parameters for untreated dynamics are: $a = 0.2$; $b = 0.6$; $c = 0.3$; $d = 0.5$; $e = 0.4$; $f = 0.1$, for Lupron only are: $a = 0.4$; $b = 0.3$; $c = 0.6$; $d = 0.5$; $e = 0.2$; $f = 0.1$, and for Lupron & Abirateron are: $a = 0.5$; $b = 0.1$; $c = 0.6$; $d = 0.2$; $e = 0.4$; $f = 0.3$.

Table 1. Competition parameters for Lupron and Abiraterone treatment

$c > e$	T^P cells have a higher fitness than T^- cells when interacting with few T^+ (absence of competition)
$a > f$	Interacting with mostly T^P cells, T^+ gains from the public good and from the new available space in low vasculature regions
$b < d$	Interacting with mostly T^- cells, T^P cells have lack of spatial competition near vasculature. Benefit to $T+$ cells, b, may be small or zero
$a > b = 0$	T^+ cells need the T^P cells to succeed in absence of systemic testosterone
$c > d$	c is likely the largest parameter as T^P cells have the highest fitness in a mostly T^- tumor without systemic testosterone
$e > f$	Again, T^P cells outcompete T^- cells without systemic testosterone

Table 2. Competition parameters for no treatment

$c < e$	T^- cells have a higher fitness than T^P cells when interacting with many T^+, especially in low vasculature regions. Testosterone production by T^P production comes at some cost to provide public good to both self (T^P) and neighbor (T^+). Both c and e should decrease in the pre-treatment condition
$a > f$	T^+ cells have a higher fitness than T^- cells when interacting with many T^P, receiving advantage from the public good. The parameter a should increase in the pre-treatment condition f slightly decrease
$b > d$	T^+ cells have a higher fitness than T^P cells when interacting with many T^- because there is lack of spatial competition near vasculature for T^+ cells as testosterone is not being used
$a < b$	T^+ cells have a higher fitness competing with T^- over competition with T^P
$c < d$	Similarly, T^P cells have a higher fitness competing with T^- over competition with T^+
$e > f$	T^- cells have less competition for space in a tumor with mostly T^+ than with mostly T^P. The parameter f should decrease in the pre-treatment condition slightly